

## Who Should Be Tested?

### Women With/Experiencing

- ✓ Unexplained Infertility
- ✓ Unexpected IVF Failure
- ✓ Limited Embryo Reserves
- ✓ Recurrent Pregnancy Loss

## What physicians are saying about ReceptivaDx testing

“ReceptivaDx provides unique information for our patients with unexplained infertility, failed IVF history and those with recurrent pregnancy loss. In the past, so many of these patients would simply give up. The test has made a significant difference for our practice.”

Sunny Jun, MD  
CCRM San Francisco  
Menlo Park, CA

“ReceptivaDx has given me insight into previously unexplained infertility and failed IVF along with treatment options for my patients.”

Mira Aubuchon, M.D.  
MCRM Fertility  
Chesterfield, MO

“Endometriosis/uterine receptivity defects are common and in this ‘no laparoscopy’ era, ReceptivaDx is essential for diagnosis and treatment planning.”

Alex Steinleitner, M.D. Physician  
Central Coast Fertility  
San Luis Obispo, CA

## Getting Tested

Over 80% of fertility centers in the US offer ReceptivaDx. In addition to fertility centers listed on our website, patients can request a collection kit for future testing at a fertility center or Ob-Gyn office near them. Everything needed to properly submit a sample is included in the kit. Please call our customer service desk at 800-795-5385 for further assistance.

## Sample Requirements

An endometrial biopsy is collected during the window of implantation in either a natural cycle or controlled “mock cycle.” Accurate biopsy timing is important to the quality of results.

7-10

days after  
ovulation

Natural Cycle

6-10

days after  
the start of  
progesterone

Mock Cycle


## Cost of Testing

A complete pathology report and interpretation of the BCL6 marker is \$690 US dollars. Optional testing to rule out endometritis (chronic bacterial infection) can be added to your ReceptivaDx panel for an additional \$145 dollars. Overnight shipping via FedEx from within the US is included in the cost. Payment is required at the time of testing before any sample can be processed. A detailed receipt will be provided to patients to help with reimbursement from insurance or healthcare spending accounts. Cicero Diagnostics does not contract with or bill insurance. International customers should email us at [info@receptivadx.com](mailto:info@receptivadx.com) for specific instructions.

## Test Results

Results are faxed to referring physicians 7-10 days from date our lab receives the sample. We cannot provide patients with results or copies of their reports. Please contact your physician if a copy is desired.

## Download ReceptivaDx App



[receptivadx.com](https://receptivadx.com) (800) 795-5385

Cicero Diagnostics is the exclusive provider of ReceptivaDx (BCL6 Analysis)

## Patient Information

BCL6 Endometrial Biopsy Analysis

### Resolving Barriers to a Successful Pregnancy



Detection of Uterine Inflammation  
& Progesterone Resistance



ReceptivaDx

## What is ReceptivaDx?

ReceptivaDx detects inflammation on the uterine lining, most often associated with endometriosis. The test can also detect recurring endometriosis in patients previously diagnosed and treated for the condition.

Endometriosis is considered to be one of the leading causes of unexplained infertility, IVF transfer failure and recurrent pregnancy loss.

ReceptivaDx provides new answers and new treatment pathways even when genetic testing of embryos and attempts to define optimal transfer windows have failed to yield a successful pregnancy.

Based on an endometrial biopsy, ReceptivaDx measures a protein called BCL6. Validation studies demonstrated a 93% sensitivity and 96% specificity between a positive BCL6 result and a confirmed diagnosis of endometriosis.

Incidence Rate of Positive BCL6 Results in Women with IVF Failure History	
IVF Failure History	% BCL6 Positive
1-2 Failures	51%
3-4 Failures	56%
5+ Failures	71%

Retrospective analysis of the relative value of IVF failures on BCL6 results - March 2022 PCRS abstract

“Women testing positive for BCL6 are 5 times less likely to succeed in IVF than women with a negative test result.”




**Bruce Lessey, M.D., Ph.D.**  
Scientific Advisor  
CiceroDx, Inc.

## What do my ReceptivaDx test results mean and what treatment options are available?

### Treatment Outcomes – BCL6 Positive Patients

Hormone Suppression vs. Laparoscopy vs. Control Group (No Treatment)



Medical or surgical treatment before embryo transfer improves outcomes in women with abnormal endometrial BCL6 expression- Journal of Assisted Reproduction and Genetics 2019 Jan 4

- If negative for BCL6, women can be confident that endometriosis is not the underlying issue and future IVF success rates will be consistent with the general IVF patient population.
- + If positive for BCL6, inflammation on the uterine lining is the likely cause of implantation failure. This inflammation is most often associated with previously undetected endometriosis.
- A treatment plan involving hormone therapy or laparoscopy to suppress or remove visible endometriosis can correct the situation.
- In a recent clinical study, BCL6 positive patients undergoing 60 days of hormone suppression therapy or laparoscopic surgery demonstrated excellent success on their next transfer attempt (see graph above).
- Risk of miscarriage was dramatically reduced in patients receiving treatment when compared to women in the control group that did not receive treatment after a positive BCL6 result.